Staph infections can be quite difficult to treat. With many staph infections resistant to antibiotic treatment, individuals who suffer from staph often find they require intravenously administered antibiotic therapy.
In the fight against antibiotic-resistant staph infections, Bristol-Myers Squibb Company has manufactured and FDA approved injection known as Kantrex. As a drug that is rapidly absorbed through intramuscular injection, Kantrex carried the strength to fight many types of antibiotic-resistant infections, including staph infections.
Following the dosing pattern of 7.5 milligrams per kilogram of weight, patients with antibiotic-resistant staph infections usually begin to notice a change in the infection in as little as one hour. While Kantrex can be administered by IV, there is no therapeutic benefit to doing so.
As an FDA approved drug, Kantrex injections do present with some side effects. Usually administered through the gluteal muscle, Kantrex is processed through the renal system and kidneys. As a result, patients who are suffering from pre-existing complications of the renal system, should be carefully monitored before and during use of Kantrex.
In addition to renal complications, nausea, vomiting and general gastrointestinal discomfort are quite common when using Kantrex injections for treatment of resistant staph infections. In addition, because the use of Kantrex may affect the neurological system, individuals who are given this antibiotic injection, as part of staph infection treatment, often report neuromuscular weakness.
As a category D drug, Kantrex is not indicated in the use of pregnant women. As an antibiotic that is quickly absorbed into the blood stream, there is a risk for passing through the placenta, affecting the development of a growing fetus. In fact, in cases of Kantrex use during pregnancy, women have reported complications involving irreversible birth defects in their newborns.
Additionally, in patients with Parkinsonism and risks for botulism, the use of Kantrex is not indicated due to the potential for adverse reactions to the muscle strength, often promoting muscle weakness in these already frail patients.
As with any form of treatment, especially when fighting antibiotic-resistant infections, it is important to discuss all of your treatment options with the health care provider. As staph infections are highly resistant to many antibiotics, the use of Kantrex injections may be the only option available for treatment. As a result, expect complications associated with GI upset and neuromuscular complications, as the antibiotic injection begins to absorb and fight the staph infection as quickly as one hour after administration.